TNSN05133A1 - Imidazoquinoline derivatives as adenosine a3 receptor ligands - Google Patents
Imidazoquinoline derivatives as adenosine a3 receptor ligandsInfo
- Publication number
- TNSN05133A1 TNSN05133A1 TNP2005000133A TNSN05133A TNSN05133A1 TN SN05133 A1 TNSN05133 A1 TN SN05133A1 TN P2005000133 A TNP2005000133 A TN P2005000133A TN SN05133 A TNSN05133 A TN SN05133A TN SN05133 A1 TNSN05133 A1 TN SN05133A1
- Authority
- TN
- Tunisia
- Prior art keywords
- adenosine
- receptor ligands
- imidazoquinoline derivatives
- imidazoquinoline
- derivatives
- Prior art date
Links
- 102000008161 Adenosine A3 Receptor Human genes 0.000 title abstract 2
- 108010060261 Adenosine A3 Receptor Proteins 0.000 title abstract 2
- 239000003446 ligand Substances 0.000 title abstract 2
- RHKWIGHJGOEUSM-UHFFFAOYSA-N 3h-imidazo[4,5-h]quinoline Chemical class C1=CN=C2C(N=CN3)=C3C=CC2=C1 RHKWIGHJGOEUSM-UHFFFAOYSA-N 0.000 title 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Otolaryngology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU0203976A HUP0203976A3 (en) | 2002-11-15 | 2002-11-15 | Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them |
| PCT/HU2003/000095 WO2004046146A1 (en) | 2002-11-15 | 2003-11-11 | Imidazoquinoline derivatives as adenosine a3 receptor ligands |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TNSN05133A1 true TNSN05133A1 (en) | 2007-05-14 |
Family
ID=90001561
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNP2005000133A TNSN05133A1 (en) | 2002-11-15 | 2005-05-10 | Imidazoquinoline derivatives as adenosine a3 receptor ligands |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US7419977B2 (https=) |
| EP (1) | EP1560828B9 (https=) |
| JP (1) | JP4533148B2 (https=) |
| KR (1) | KR20050088291A (https=) |
| CN (1) | CN1332960C (https=) |
| AR (1) | AR041968A1 (https=) |
| AT (1) | ATE325123T1 (https=) |
| AU (1) | AU2003282263B2 (https=) |
| BR (1) | BR0316355A (https=) |
| CA (1) | CA2505910C (https=) |
| CO (1) | CO5690577A2 (https=) |
| CY (1) | CY1105180T1 (https=) |
| DE (1) | DE60305058T2 (https=) |
| DK (1) | DK1560828T3 (https=) |
| EA (1) | EA007595B1 (https=) |
| ES (1) | ES2263039T3 (https=) |
| HR (1) | HRP20050540A2 (https=) |
| HU (1) | HUP0203976A3 (https=) |
| IL (1) | IL168516A (https=) |
| IS (1) | IS2456B (https=) |
| MA (1) | MA27501A1 (https=) |
| ME (1) | MEP19008A (https=) |
| MX (1) | MXPA05005198A (https=) |
| NO (1) | NO20052866D0 (https=) |
| NZ (1) | NZ540029A (https=) |
| PL (1) | PL376837A1 (https=) |
| PT (1) | PT1560828E (https=) |
| RS (1) | RS51320B (https=) |
| SI (1) | SI1560828T1 (https=) |
| TN (1) | TNSN05133A1 (https=) |
| TW (1) | TWI248934B (https=) |
| UA (1) | UA78889C2 (https=) |
| WO (1) | WO2004046146A1 (https=) |
| ZA (1) | ZA200503807B (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0105406A3 (en) * | 2001-12-21 | 2003-12-29 | Sanofi Aventis | Imidazo[1,2-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates |
| HUP0203976A3 (en) * | 2002-11-15 | 2004-08-30 | Sanofi Aventis | Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them |
| HUP0400812A2 (en) * | 2004-04-19 | 2006-02-28 | Sanofi Aventis | Crystalline forms of 2-amino-3-cyano-quinoline derivatives, process for their preparation and pharmaceutical compositions containing them |
| GT200600381A (es) | 2005-08-25 | 2007-03-28 | Compuestos organicos | |
| US20090088403A1 (en) * | 2007-05-07 | 2009-04-02 | Randy Blakely | A3 adenosine receptors as targets for the modulation of central serotonergic signaling |
| HUP0700395A2 (en) * | 2007-06-07 | 2009-03-02 | Sanofi Aventis | Substituted [1,2,4] triazolo [1,5-a] quinolines, process for their preparation, pharmaceutical compositions thereof, and intermediates |
| WO2011010306A1 (en) | 2009-07-21 | 2011-01-27 | Ramot At Tel-Aviv University Ltd. | A3 adenosine receptor ligands for modulation of pigmentation |
| WO2014120995A2 (en) | 2013-02-01 | 2014-08-07 | Wellstat Therapeutics Corporation | Amine compounds having anti-inflammatory, antifungal, antiparasitic and anticancer activity |
| KR101820909B1 (ko) * | 2017-07-07 | 2018-01-23 | 퓨쳐메디신 주식회사 | 아데노신 유도체를 포함하는 만성신장질환 예방 및 치료용 약학적 조성물 |
| TWI795440B (zh) | 2017-09-15 | 2023-03-11 | 美商佛瑪治療公司 | 作為ＣＢＰ／ｐ３００抑制劑之四氫─咪唑並喹啉化合物 |
| US10870648B2 (en) | 2018-06-29 | 2020-12-22 | Forma Therapeutics, Inc. | Inhibiting CREB binding protein (CBP) |
| WO2020190791A1 (en) | 2019-03-15 | 2020-09-24 | Forma Therapeutics, Inc. | Inhibiting cyclic amp-responsive element-binding protein (creb) |
| BR112021016921A2 (pt) * | 2019-03-15 | 2021-11-03 | Forma Therapeutics Inc | Inibição de proteína de ligação a elemento responsivo a amp cíclico (creb) |
| US11801243B2 (en) | 2020-09-23 | 2023-10-31 | Forma Therapeutics, Inc. | Bromodomain inhibitors for androgen receptor-driven cancers |
| US11795168B2 (en) | 2020-09-23 | 2023-10-24 | Forma Therapeutics, Inc. | Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP) |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4075343A (en) * | 1976-09-13 | 1978-02-21 | Pfizer Inc. | Anti-allergenic 5-alkoxyimidazo[1,2-A]quinoline-2-carboxylic acids and derivatives thereof |
| GB1596652A (en) * | 1977-01-20 | 1981-08-26 | Roussel Lab Ltd | Imidazo (1,2-a) quinoline-2-carboxylic acid and derivatives |
| FR2448541A1 (fr) | 1979-02-09 | 1980-09-05 | Roussel Uclaf | Nouveaux derives de l'oxoimidazoquinoxaline et leurs sels, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant |
| SE441449B (sv) | 1979-02-09 | 1985-10-07 | Roussel Uclaf | Heterocykliska derivat och farmaceutiska kompositioner innehallande dessa derivat |
| US4644002A (en) | 1979-02-09 | 1987-02-17 | Roussel Uclaf | Imidazo[2,1-C]quinolines, useful as antiallergic agents |
| CA2336967C (en) | 1998-07-10 | 2010-06-29 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | A3 adenosine receptor antagonists |
| US6448253B1 (en) * | 1998-09-16 | 2002-09-10 | King Pharmaceuticals Research And Development, Inc. | Adenosine A3 receptor modulators |
| AU768520B2 (en) | 1999-09-28 | 2003-12-18 | Otsuka Pharmaceutical Factory, Inc. | Triazolopurine derivatives, drug compositions containing the same and adenosine A3 receptor affinitive agents |
| US7160890B2 (en) * | 1999-12-02 | 2007-01-09 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
| CA2430577A1 (en) * | 2000-12-01 | 2002-07-25 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine a1, a2a, and a3 receptor and uses thereof |
| EP1390349B1 (en) * | 2001-05-31 | 2012-07-25 | Sanofi | Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands |
| HUP0105406A3 (en) | 2001-12-21 | 2003-12-29 | Sanofi Aventis | Imidazo[1,2-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates |
| HUP0105407A3 (en) * | 2001-12-21 | 2004-04-28 | Sanofi Aventis | Triazolo[1,5-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates |
| HUP0203976A3 (en) | 2002-11-15 | 2004-08-30 | Sanofi Aventis | Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them |
-
2002
- 2002-11-15 HU HU0203976A patent/HUP0203976A3/hu unknown
-
2003
- 2003-11-11 EA EA200500830A patent/EA007595B1/ru unknown
- 2003-11-11 CA CA2505910A patent/CA2505910C/en not_active Expired - Fee Related
- 2003-11-11 PT PT03773882T patent/PT1560828E/pt unknown
- 2003-11-11 SI SI200330299T patent/SI1560828T1/sl unknown
- 2003-11-11 RS YUP-2005/0364A patent/RS51320B/sr unknown
- 2003-11-11 HR HR20050540A patent/HRP20050540A2/xx not_active Application Discontinuation
- 2003-11-11 PL PL376837A patent/PL376837A1/pl not_active Application Discontinuation
- 2003-11-11 DE DE60305058T patent/DE60305058T2/de not_active Expired - Lifetime
- 2003-11-11 EP EP03773882A patent/EP1560828B9/en not_active Expired - Lifetime
- 2003-11-11 NZ NZ540029A patent/NZ540029A/en not_active IP Right Cessation
- 2003-11-11 BR BR0316355-5A patent/BR0316355A/pt not_active IP Right Cessation
- 2003-11-11 ME MEP-190/08A patent/MEP19008A/xx unknown
- 2003-11-11 DK DK03773882T patent/DK1560828T3/da active
- 2003-11-11 AT AT03773882T patent/ATE325123T1/de active
- 2003-11-11 KR KR1020057008683A patent/KR20050088291A/ko not_active Abandoned
- 2003-11-11 CN CNB2003801062293A patent/CN1332960C/zh not_active Expired - Fee Related
- 2003-11-11 UA UAA200505875A patent/UA78889C2/uk unknown
- 2003-11-11 AU AU2003282263A patent/AU2003282263B2/en not_active Ceased
- 2003-11-11 MX MXPA05005198A patent/MXPA05005198A/es active IP Right Grant
- 2003-11-11 JP JP2004552920A patent/JP4533148B2/ja not_active Expired - Fee Related
- 2003-11-11 WO PCT/HU2003/000095 patent/WO2004046146A1/en not_active Ceased
- 2003-11-11 ES ES03773882T patent/ES2263039T3/es not_active Expired - Lifetime
- 2003-11-14 AR ARP030104200A patent/AR041968A1/es unknown
- 2003-11-14 TW TW092131901A patent/TWI248934B/zh not_active IP Right Cessation
-
2005
- 2005-05-10 IL IL168516A patent/IL168516A/en not_active IP Right Cessation
- 2005-05-10 TN TNP2005000133A patent/TNSN05133A1/en unknown
- 2005-05-11 ZA ZA200503807A patent/ZA200503807B/en unknown
- 2005-05-16 US US11/130,429 patent/US7419977B2/en not_active Expired - Fee Related
- 2005-05-31 IS IS7874A patent/IS2456B/is unknown
- 2005-06-13 NO NO20052866A patent/NO20052866D0/no not_active Application Discontinuation
- 2005-06-13 MA MA28334A patent/MA27501A1/fr unknown
- 2005-06-14 CO CO05057645A patent/CO5690577A2/es not_active Application Discontinuation
-
2006
- 2006-07-28 CY CY20061101054T patent/CY1105180T1/el unknown
-
2008
- 2008-06-17 US US12/140,512 patent/US7709489B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA03006093A (es) | Derivados de n(fenilsulfonil)glicina y su uso terapeutico. | |
| IL155702A0 (en) | Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5-ht2 receptor | |
| AU1529402A (en) | Piperazinylpyrazines compounds as antagonists of serotonin 5-ht2 receptor | |
| AU2003228770A8 (en) | Substituted pyrazolopyrimidines | |
| TNSN05133A1 (en) | Imidazoquinoline derivatives as adenosine a3 receptor ligands | |
| GB0130341D0 (en) | Compounds | |
| IL150085A0 (en) | New-p2x7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases | |
| PL377295A1 (pl) | Pochodne 4,5-diarylotiazolu jako ligandy CB-1 | |
| YU39803A (sh) | Jedinjenja piperazinilpirazina kao agonisti ili antagonisti serotonin 5ht-2-receptora | |
| YU80902A (sh) | Novi indolin-2-on derivati, njihovo dobijanje i farmaceuski oblici koji ih sadrže | |
| WO2006059149A8 (en) | Arylsulfonylnaphthalene derivatives as 5ht2a antagonists | |
| NZ552137A (en) | New 4-benzylidene-piperidin derivatives | |
| IS7507A (is) | Ný efnasambönd | |
| BG106930A (en) | Substituted phenyl-piperazine derivatives, their preparation and use | |
| MXPA05013149A (es) | Derivados de imidazol como antagonistas del receptor de glutamato. | |
| MXPA05010651A (es) | Compuestos de pirazol. | |
| ATE274515T1 (de) | Pyrazolopyridinderivate | |
| DE60100539D1 (en) | Tosylprolin-derivate als thymidylat-synthase inhibitoren | |
| ZA200408029B (en) | Novel 1,3,5-triazine derivatives as ligands for human adenosine-A3 receptors. | |
| IL173582A0 (en) | A process for the preparation of phenyltetrazole derivatives | |
| PL375350A1 (en) | Indol derivatives and their use as 5-ht ligands | |
| TNSN06410A1 (en) | Pyrrolopyridine derivatives and their use as crth2 antagonists | |
| IS8034A (is) | Imídasó[4,5-B]kínólínafleiður og notkun þeirra sem NO-myndunarhemla | |
| GEP20074180B (en) | Substituted benzol[e] [1,4] oxazino[3,2-g] isoindole derivatives, method for preparing same and pharmaceutical compositions containing same | |
| YU39603A (sh) | Jedinjenja piperazinilpirazina kao antagonisti serotonin 5-ht2 receptora |